Stella Diagnostics (Stella Diagnostics) Gross-Profit-to-Asset % : 0.00% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Stella Diagnostics's annualized Gross Profit for the quarter that ended in Sep. 2023 was $0.00 Mil. Stella Diagnostics's average Total Assets over the quarter that ended in Sep. 2023 was $0.44 Mil. Therefore, Stella Diagnostics's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 was 0.00%.

Stella Diagnostics Gross-Profit-to-Asset % Historical Data

The historical data trend for Stella Diagnostics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Gross-Profit-to-Asset % Chart

Stella Diagnostics Annual Data

Trend

Gross-Profit-to-Asset %

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Gross-Profit-to-Asset %	-	-

Competitive Comparison of Stella Diagnostics's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, Stella Diagnostics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stella Diagnostics's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Stella Diagnostics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Stella Diagnostics's Gross-Profit-to-Asset % falls into.

Stella Diagnostics Gross-Profit-to-Asset % Calculation

Stella Diagnostics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in . 20 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: . 20 )	/	( (Total Assets (A: . 20 )	+	Total Assets (A: . 20 ))	/ count )
	=		/	( (	+	)	/ )
	=		/
	=	%

Stella Diagnostics's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2023 )	/	( (Total Assets (Q: Sep. 2022 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	0	/	( (0	+	0.441)	/ 1 )
	=	0	/	0.441
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Stella Diagnostics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.